We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,140

Astrazeneca Canada Inc. v. Apotex Inc., 2015 FC 671
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2015

The parties moved under Rule 397 to modify the terms of the judgment in the proceeding, previously reported as 2015 FC 322 and summarized in our


Innovator delays its own Canadian drug approval in effort to secure data protection
  • McCarthy Tétrault LLP
  • Canada
  • July 10 2015

On June 12, 2015, at the urgent request of Horizon Pharma PLC (“Horizon”), the Federal Court of Canada granted a rare interlocutory stay preventing


Supreme Court dismisses appeal from the bench in Sanofi-Aventis v. Apotex, Inc.
  • Bereskin & Parr LLP
  • Canada
  • May 8 2015

On April 21st, 2015, the Supreme Court of Canada dismissed from the bench an appeal from the Federal Court of Appeal decision inApotex Inc. v


Federal Court of Appeal holds PMNOC appeal moot - innovator argument on CETA equal access to appeal right rejected
  • Norton Rose Fulbright Canada LLP
  • Canada
  • February 12 2015

Janssen Inc. et al. (Janssen) appealed from the decision of Justice Barnes of the Federal Court refusing to prohibit the Minister of Health from


Bayer Inc. v. Cobalt Pharmaceuticals Company, 2013 FC 1061 : methods of medical treatment held unpatentable, promise of a patent must be explicit
  • Heenan Blaikie LLP
  • Canada
  • November 11 2013

On October 22, 2013, the Federal Court released its decision regarding Bayer's application to prohibit the Minister of Health from issuing Cobalt a


When is a little knowledge a dangerous thing? When it is used to disqualify in-house counsel
  • McCarthy Tétrault LLP
  • Canada
  • February 28 2014

A powerful tool in the litigation arsenal is the bringing of a motion to remove counsel from a file, either because she possesses disqualifying


Pharma in brief - SCC invited to revisit key patent issues: standard of review of claims construction and the patentability of methods of medical treatment
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 14 2015

Bayer Inc. (Bayer) distributes a combination oral contraceptive tablet under the brand name YAZ (drospirenone and ethinylestradiol


The U.S. Federal Court of Appeals agrees that prenatal diagnostic methods are not patent eligible
  • Fasken Martineau DuMoulin LLP
  • Canada
  • June 30 2015

The United States Court of Appeals for the Federal Circuit issued its decision in Ariosa Diagnostics Inc. et al. V. Sequenom Inc. (PDF), case number


Is the Competition Bureau targeting you? New IP enforcement guidelines
  • Bennett Jones LLP
  • Canada
  • June 12 2015

On June 9, 2015, the Canadian Competition Bureau released updated draft Intellectual Property Enforcement Guidelines (IPEGs) for public comment. The


Federal Court of Appeal affirms rejection of heightened sound prediction patent disclosure requirements
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 12 2015

Allergan obtained a prohibition order against Apotex under section 6 of the PMNOC Regulations with respect to the drug bimatoprost